COVID-19: Valneva expects “over 80%” effect for his vaccine

Paris | Franco-Austrian laboratory Valneva is in the advanced stages of testing for its candidate vaccine against COVID-19, its general manager Frank Grimoud announced on Tuesday.

“Based on the Phase I and II trials (…) we expect the vaccine to be more than 80% effective. .

So messenger RNA vaccines are less effective than 95% of them, such as Pfizer / BioMtech or Modernna. But it is more than just estrogen and Johnson & Johnson vaccines, which work by viral vector and are between 60 and 70%.

Valneva uses the deactivated virus vaccine, which is a more traditional technique than RNA, and is used exclusively for influenza vaccines each year.

“The vaccine has all the parameters to have a good mix of its effectiveness, risk, duration of protection, duration between the first two doses and the need for a booster.” Defended by Frank Grimoud.

The lab submitted its request for authority to British health officials on Monday. According to Mr Grimoud, the United Kingdom has already ordered 100 million doses for 2021-2022, but negotiations with the European Union are ongoing.

Valneva’s CEO believes that “regular vaccinations” are needed to fight COVID-19 in the coming years. “We need to vaccinate adolescents and children as well, and the vaccine, like ours, is of interest with its safety profile,” he believes.

It is aimed at “a section of the population that is hesitant about new vaccine technologies” as well as in countries where vaccination is still difficult.